Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic
approach to treat metastatic prostate cancer. This tumor-specific treatment is directed
against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer
cells. In the last few years, several lutetium-177 (177Lu, β emitter) labeled PSMA ligands
have been developed and are currently applied to treat metastatic castrate resistant prostate
cancer patients. To date, there are no prospective randomized studies published using this
treatment in the hormone sensitive setting or in oligometastatic prostate cancer. Therefore,
this study we will evaluate the effect of 177Lu-PSMA in patients with hormone sensitive
oligo-metastatic prostate cancer.